PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a […]
Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.
ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI) and dementia (DEM). Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 750 participants will be newly
Hearing Aid Research Are you interested in participating in hearing aid research? Dr. Zhang is collaborating with Dr. Wei Sun at UB and is recruiting people over the age of 18 who have tinnitus and hearing loss. Participants will be compensated for their time. This study will require you to wear hearing aids for 3-4
Hearing Aid Research Read More »
Meniere’s Study Have you been diagnosed with Meniere’s Disease? Do you frequently experience vertigo? If you answered yes to these questions and are over the age of 18, you may qualify for a research study. Qualified participants will receive at no cost: All study-related exams Study drug or placebo (no active ingredient) If you are
A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, an identified adult who has sufficient contact to knowledgeably report on the subject’s daily cognition, function, behavior, safety, compliance and adherence. Have a clinical diagnosis of mild-to-moderate AD Visual and
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Read More »
